Method and apparatus for the in vivo measurement of oxygen concentration levels by the indirect determination of fluoescence lifetime

• US 5,515,864 A
• Filed: 04/21/1994
• Issued: 05/14/1996
• Est. Priority Date: 04/21/1994
• Status: Expired due to Term

• Current Assignee: Cellview Imaging Inc.
• Original Assignee: Ralph Zuckerman
• Inventors: Zuckerman, Ralph
• Primary Examiner(s): Sykes, Angela D.
• Assistant Examiner(s): WINAKUR, ERIC FRANK
• Application Number:
  US08/231,191
• Time in Patent Office: 754 Days
• Field of Search: 128/665, 128/633, 128/634, 356/41
• US Class Current: 600/311
• CPC Class Codes: A61B 5/14555 specially adapted for the eye fundus
• CPC Class Codes: G01N 21/6445 Measuring fluorescence polarisation

Abstract

Methods are described for the in vivo topographic determination of tissue and bodily fluid oxygen concentration or PO₂ within an imaged tissue, as well as a method for measuring blood or bodily fluid PO₂ with a fiber optic catheter. In the first method, a lipid soluble, biocompatible fluorescent probe substance is administered to an animal body and accumulates within the lipid bilayers of its tissue cells. In the second method, the fluorescent probe substance is conjugated to a large molecular mass protein which causes it to be retained within a bodily fluid such as blood. In the third method describing a catheter design, in which PO₂ is measured at the catheter tip, the tip contains the fluorescent probe substance dissolved in a viscous nonpolar solvent. In all methods described, a fluorescent probe substance is preferred whose fluorescence lifetime is quenched by molecular oxygen, and oxygen concentration or PO₂ is determined by measuring the fluorescence anisotropy of the fluorescent probe substance. The bodily fluid or tissue containing the biocompatible fluorescent probe substance, or the fluorescent probe substance in a nonpolar solvent within a catheter tip, is irradiated with continuous linearly polarized ultraviolet light at a wavelength strongly absorbed by the fluorophore. The emitted fluorescence is resolved into its vector components parallel and perpendicular to the plane of polarization of the excitation light, thereby permitting the calculation of the fluorescence anisotropy of the irradiated specimen. Tissue and/or bodily fluid PO₂ of the imaged specimen, or the PO₂ of a fluid at the tip of a sealed catheter, is determined by applying a mathematical function which relates the fluorescence anisotropy of an O₂ -quenchable fluorophore to oxygen concentration or partial pressure.

Claims

1. A method of measuring oxygen concentration or partial pressure in bodily fluid or tissue of a living being, the method comprising the steps of:

(a) administering a biocompatible, lipid soluble fluorescent probe substance having a fluorescence lifetime (τ

) which is quenched by molecular oxygen, to the living being;

(b) irradiating the tissue or bodily fluid with continuous, linearly polarized ultraviolet light at wavelengths strongly absorbed by the fluorescent probe substance to result in fluorescence having vector components parallel and perpendicular to the plane of polarization of the ultraviolet light;

(c) resolving the fluorescence emitted from the irradiated tissue or bodily fluid of step (b) into vector components parallel and perpendicular to the plane of polarization of the excitation light;

(d) calculating fluorescence anisotropy in space or in time of the tissue or fluid so irradiated; and

(e) applying a mathematical function which relates fluorescence anisotropy to oxygen concentration or partial pressure, the mathematical function being in the form of an equation.

2. The method of claim 1 additionally comprising the step of selecting the equation as follows:

##EQU9## wherein α

is a Bunsen solubility coefficient, K_D is a dynamic quench constant, and τ

_o is a fluorescence lifetime in the absence of O₂.

3. The method of either of claims 1 or 2 additionally comprising the step of selecting the biocompatible fluorescent probe substance to have an O₂ -quenchable fluorescence lifetime ranging between about 30 to 135 nanoseconds.

4. The method of claim 1 additionally comprising the step of selecting the equation as follows:

##EQU10## wherein A is fluorescence anisotropy defined as ##EQU11## wherein I.sub.∥ and

I.sub.⊥

are intensities of fluorescence emission having electric vectors respectively parallel and perpendicular to that of linearly polarized exciting radiation, G is an empirical correction factor used to correct for transmission efficiency in parallel and perpendicular planes, R is mean molecular rotation time in radians/sec, A_o is fluorescence anisotropy in a "frozen" state, in the absence of Brownian rotation, α

is a Bunsen solubility coefficient, K_D is a dynamic quench constant, and τ

_o is fluorescence lifetime in the absence of O₂.

5. The method of any one of claims 1, 2, or 4 wherein a topographic distribution of tissue or blood PO₂ of an imaged tissue and vasculature is determined.

6. The method of claim 5 wherein the biocompatible, fluorescent probe substance accumulates within lipid bilayers of tissue and red blood cell membranes.

7. The method of claim 6 wherein fluorescence anisotropy values of less than 0.4 are obtained.

8. The method of claim 5 wherein the fluorescent probe substance is conjugated to a large molecular mass protein and is retained within the vasculature of the imaged tissue, or is retained within a bodily fluid other than blood.

9. The method of claim 8 additionally comprising the step of selecting the large molecular mass protein to be albumin.

10. The method of claims 5 additionally comprising the step of selecting the biocompatible, lipid soluble fluorescent probe substance to be pyrenebutyric acid or a salt form thereof.

11. The method of claim 5 wherein the biocompatible, lipid soluble fluorescent probe substance is applied topically in a solution.

12. The method of claim 11 wherein the solution is physiologic saline or dimethyl sulfoxide.

13. The method of any one of claims 1 and 4 wherein PO₂ - or oxygen concentration-dependent anisotropy of the tissue or bodily fluid in the presence of the fluorescent probe substance (A(PO₂) or A_probe) may be determined from anisotropy of the tissue or bodily fluid in the absence of the fluorescent probe substance (A_tissue) by an equation as follows:

##EQU12## wherein A_total is total anisotropy (A_probe plus A_tissue) of an imaged specimen, and a is an empirical constant determined in prior calibration.

14. The method of any one of claims 1, 2, or 4 wherein a topographic distribution of tissue or fluid PO₂ is determined tomographically within a volume of an imaged imaged tissue by means of optical serial sectioning methodologies.

15. The method of claim 14 additionally comprising the step of selecting the optical serial sectioning methodology to be confocal microscopy.

16. The method of claim 14 additionally comprising the step of selecting the optical serial sectioning methodology to be digital deconvolution procedures.

17. The method of claim 1 wherein the lipid soluble fluorescent probe substance is administered intravenously in solution.

18. The method of claim 1 wherein the lipid soluble fluorescent probe substance is administered intravenously by incorporating the fluorescent probe substance in liposomes and then intravenously administering the liposomes to the living being.

19. The method of either of claims 1 or 8 wherein the fluorescent probe substance is conjugated to a large molecular mass protein and is administered intravenously.

20. The method of claim 1 wherein the biocompatible fluorescent probe substance is exposed to linearly polarized light having wavelengths less than about 400 nm.